Ultibro Breezhaler 110/ 50 μg Dry powder inhalation capsules
PDF Leaflet Revision Date: 23 August 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of COPD in symptomatic patients despite LABA or LAMA.
Dosage (summary)
Once daily inhalation of one 110/50 u03bcg capsule.
Onset of Action / Duration
Onset: 15 mins, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; may inhibit labor.
Key Drug Interactions
- Beta-adrenergic blockers
- QT prolonging medications
- Other sympathomimetics
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Severe hepatic impairment
Common side effects
- Upper respiratory tract infection
- Headache
- Dizziness
- Dry mouth
Counselling Points
- Inhale deeply and hold breath after use.
- Do not swallow capsules.
- Store capsules in blister until use.
Serious warnings
- Paradoxical bronchospasm
- Hypersensitivity reactions
- Not for asthma treatment
Important Disclaimer
The Ultibro Breezhaler 110/ 50 μg Dry powder inhalation capsules professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
